Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
huJ591 in High/Intermediate-Risk Prostate Cancer
NCT02693860Phase 1Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2016
- Primary completion
- Feb 2017
- Modality
- Engineered Antibody Formats, Antibody-Radionuclide Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of huJ591 in prostate cancer (PCa), sponsored by Weill Cornell Medicine. Primary endpoint: Peri-tumoral inflammation 4-point scoring at Day 31. Started Feb 2016; status: completed.
02
Drugs
huJ591
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02693860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02693860.